Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP902661.RAWl0QPRM5-EDlJpHdiMdQ7xGkUSII5WHLe1C925yOYtY130_assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP902661.RAWl0QPRM5-EDlJpHdiMdQ7xGkUSII5WHLe1C925yOYtY130_provenance.
• NP810128.RAWgdCJWoSlXmTXG4pUASVezclQVZzkDJCDFx33hKjIjE130_assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP810128.RAWgdCJWoSlXmTXG4pUASVezclQVZzkDJCDFx33hKjIjE130_provenance.
• NP849728.RAfEDUzo5ezpxs-UjYU0WAgALvDeJjcGois9rIEkTuEK8130_assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP849728.RAfEDUzo5ezpxs-UjYU0WAgALvDeJjcGois9rIEkTuEK8130_provenance.
• NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP876633.RAdLwFr72BKr0IcQtVVVmi0x98At9o3dfqq0z6-lXyark130_provenance.
• assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP441527.RAnpJJy-OWYImYqt6cW2c5zbs0qsZ-29jB-RH8cSSdr6A130_assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP441527.RAnpJJy-OWYImYqt6cW2c5zbs0qsZ-29jB-RH8cSSdr6A130_provenance.
• NP1086111.RAq0DJNeKIQoU-8Y6Gx_Zc3Mx44HvR5-AU_aUvaR-2hv4130_assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1086111.RAq0DJNeKIQoU-8Y6Gx_Zc3Mx44HvR5-AU_aUvaR-2hv4130_provenance.
• NP1086114.RAoPH7umtkdAktDTgYQyrsdcgLaMPuRkK2TF68b6nP0VE130_assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1086114.RAoPH7umtkdAktDTgYQyrsdcgLaMPuRkK2TF68b6nP0VE130_provenance.
• NP1086116.RAKYpPAnWn8ojMN3NQQTYim5oYS3TnA0rA8xjUbKMFWTA130_assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1086116.RAKYpPAnWn8ojMN3NQQTYim5oYS3TnA0rA8xjUbKMFWTA130_provenance.
• NP1086112.RA0w6qn1LjXv5canMlKkwDsuo0uanLdZiGjgk2-dAG8Zs130_assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1086112.RA0w6qn1LjXv5canMlKkwDsuo0uanLdZiGjgk2-dAG8Zs130_provenance.
• NP1086115.RA_SZiVlj9b9O0zO2m6muJNCEI_Ye6SMEQlWbkV8Ty_0c130_assertion description "[Erlotinib treatment at clinically relevant concentrations induced autophagy (increased LC3II expression, Atg-5/Atg12 conjugation, formation of AVO and p62 degradation) in sensitive NSCLC cell lines, via p53 nuclear translocation, AMPK activation and mTOR suppression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1086115.RA_SZiVlj9b9O0zO2m6muJNCEI_Ye6SMEQlWbkV8Ty_0c130_provenance.